Intravesical immunotherapy in nonmuscle invasive bladder cancer

about

Circulating microRNAs, miR-92a, miR-100 and miR-143, as non-invasive biomarkers for bladder cancer diagnosis.A Case of Epididymo-orchitis after intravesical bacille Calmette-Guérin therapy for superficial bladder carcinoma in a patient with latent tuberculosis infection.

P2860

Q39967840-2414D94A-EF99-47C9-8FA0-4898C876B4E4 Q40647471-AD50C81D-A8AD-44D1-8810-E3116997F077

P2860

Intravesical immunotherapy in nonmuscle invasive bladder cancer

Item

http://www.wikidata.org/entity/Q26775979

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Intravesical immunotherapy in nonmuscle invasive bladder cancer

@ast

Intravesical immunotherapy in nonmuscle invasive bladder cancer

@en

Intravesical immunotherapy in nonmuscle invasive bladder cancer

@nl

type

Item

label

Intravesical immunotherapy in nonmuscle invasive bladder cancer

@ast

Intravesical immunotherapy in nonmuscle invasive bladder cancer

@en

Intravesical immunotherapy in nonmuscle invasive bladder cancer

@nl

prefLabel

Intravesical immunotherapy in nonmuscle invasive bladder cancer

@ast

Intravesical immunotherapy in nonmuscle invasive bladder cancer

@en

Intravesical immunotherapy in nonmuscle invasive bladder cancer

@nl

P1476

Intravesical immunotherapy in nonmuscle invasive bladder cancer

@en

P2093

Alexander Karl

http://www.w3.org/2001/XMLSchema#string

Jan-Friedrich Jokisch

http://www.w3.org/2001/XMLSchema#string

P2860

Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer

Cancer statistics, 2010

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).

Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study Group.

BCG immunotherapy of bladder cancer: 20 years on.

Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer.

Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response

Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.

Immunotherapy for bladder cancer.

P304

304-11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1076797

http://www.w3.org/2001/XMLSchema#string

P356

10.4103/0970-1591.166452

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christian G Stief

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26604441

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

4626914

http://www.w3.org/2001/XMLSchema#string

Intravesical immunotherapy in nonmuscle invasive bladder cancer

about

P2860

P2860

Intravesical immunotherapy in nonmuscle invasive bladder cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P3181

P356

P407

P433

P478

P50

P577

P698

P921

P932

P3181

P356

P1433

P1476

P2093

P2860

P304

P31

P3181

P356

P407

P433

P478

P50

P577

P698

P921

P932